Essais cliniques au Canada

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

This was a two-part (Phase 2/3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension. Phase 2 assessed three different doses of MK-5475 compared to placebo. Phase 3’s purpose was to confirm the efficacy, safety, and tolerability of MK-5475 at the selected dose compared to placebo during a 12 week base period followed by an extension period of up to 5 years.

The purpose of this study was to assess the safety and efficacy of rodatristat ethyl in pulmonary arterial hypertension (PAH) patients. Rodatristat ethyl is a peripherally restricted tryptophan hydroxylase inhibitor being studied as a potential treatment for PAH.

The objectives of this study were to evaluate the efficacy and safety of sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with pulmonary arterial hypertension.

The primary objective for this trial was to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization Group 1 PAH who are Functional Class II and III. The secondary objective for this trial was to determine the effect of seralutinib on improving exercise capacity in this population.

This study evaluated the impact of a 12 week home-based rehabilitation program on peripheral muscle function and metabolism, focusing on lipid infiltration, oxidative metabolism and epigenetic factors that can be involved in metabolic syndrome, in patients with pulmonary arterial hypertension.

Extended the investigator's preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension.

This study aimed to demonstrate that the fixed-dose combination (FDC) of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study evaluated the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two pulmonary-arterial-hypertension-approved therapies given as monotherapy to further confirm the added value of the FDC.

The investigators looked at whether or not metabolic syndrome seen in pulmonary arterial hypertension patients impairs mitochondrial functions through an IRS1/PPARg/PGC1-dependent mechanism, which would ultimately decrease skeletal muscle function and perfusion, and thus overall exercise capacity.

Using new sophisticated technology, the investigators will determine the root causes of perceived breathing difficulty. The investigators will test the idea that breathlessness is fundamentally the result of increased drive to breathe from control centers in the brain. The investigators will measure drive to breathe by measuring the electrical activity descending from the brain to the main muscle of breathing - the diaphragm.

To investigate if the inflammatory protein, high mobility group box 1 (HMGB1), along with other inflammatory mediators, is elevated in pediatric patients with congenital heart disease (CHD) and pulmonary hypertension as compared to those with CHD alone, or with healthy controls.

The purpose of this study was to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.

The primary objective of this study was to develop new, sensitive, quantitative echocardiographic diagnostic criteria which will allow for the identification of extreme preterm neonates suffering from significantly high pressure in their pulmonary blood vessels, early in postnatal course, when the disease is likely to be most amenable to preventative/curative treatment.

To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

The TOPP-2 registry is an international, non-interventional, prospective registry including children and adolescents newly diagnosed with pulmonary hypertension (PH) to gain further insights in the disease course and long-term outcome of PH in childhood.

This study was an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who had completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.

Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)

The aim of this study was to assess whether increasing oral doses of riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction.